|1.||Hartley, John A: 4 articles (06/2011 - 09/2004)|
|2.||Spanswick, Victoria J: 3 articles (06/2011 - 09/2004)|
|3.||Lee, Wooin: 3 articles (06/2011 - 01/2008)|
|4.||Thurston, David E: 3 articles (09/2004 - 09/2004)|
|5.||Puzanov, Igor: 2 articles (06/2011 - 01/2008)|
|6.||Rothenberg, Mace L: 2 articles (06/2011 - 01/2008)|
|7.||Calcutt, M Wade: 2 articles (06/2011 - 04/2010)|
|8.||Hachey, David L: 2 articles (06/2011 - 01/2008)|
|9.||Hochhauser, Daniel: 2 articles (03/2009 - 09/2004)|
|10.||Clingen, Peter H: 2 articles (03/2009 - 09/2004)|
06/01/2011 - "Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors."
04/01/2010 - "We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor. "
04/01/2010 - "For patients with advanced solid tumors, the MTD of SJG-136 is 40 microg/m2/day administered on days 1, 8 and 15 of a 28-day cycle. "
04/01/2010 - "PK parameters of SJG-136 were assessed following the intravenous administration of SJG-136 on days 1 and 15 of cycle 1. Twenty-one patients with advanced solid tumors were treated. "
01/01/2009 - "SJG-136 is currently undergoing Phase I evaluation in both the United States (through the NCI) and United Kingdom (through Cancer Research United Kingdom). "
|2.||Ovarian Neoplasms (Ovarian Cancer)
|3.||Colonic Neoplasms (Colon Cancer)
|4.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
09/15/2004 - "Given this profile, we undertook a preclinical evaluation of SJG-136 in primary tumor cells derived from 34 B-cell chronic lymphocytic leukemia (B-CLL) patients. "
09/15/2004 - "The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill."
|5.||Melanoma (Melanoma, Malignant)
09/15/2004 - "In the current investigation, SJG-136 was evaluated for in vivo efficacy in 10 tumor models selected on the basis of sensitivity of cells grown in the hollow fiber and in vitro time course assays: LOX IMVI and UACC-62 (melanomas); OVCAR-3 and OVCAR-5 (ovarian carcinomas); MDA-MB-435 (breast carcinoma); SF-295 and C-6 (gliomas); LS-174T (colon carcinoma); HL-60 TB (promyelocytic leukemia); and NCI-H522 (lung carcinoma). "
|1.||1,1'- ((propane- 1,3- diyl)dioxy)bis(7- methoxy- 2- methylidene- 1,2,3,10,11,11a- hexahydro- 5H- pyrrolo(2,1- c)(1,4)benzodiazepin- 5,11- dione)
|2.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)